Clinical Updates Regarding Multiple Myeloma From the 2019 American Society of Hematology Annual Meeting.

In this review, we summarize novel clinical data on multiple myeloma (MM) that were presented at the 2019 annual meeting of the American Society of Hematology. The Master trial showed that a response-adapted approach may effectively guide therapeutic decisions in terms of treatment intensification after autologous transplantation among patients with newly diagnosed MM. The Alcyone study confirmed the superiority of adding daratumumab to the backbone combination of bortezomib, melphalan, and dexamethasone among diagnosed MM patients unfit for transplantation, which resulted in a significant overall survival benefit. The Candor trial showed that the addition of daratumumab to carfilzomib and dexamethasone is associated with a significant benefit in progression-free survival among patients with relapsed/refractory MM after 1 to 3 prior lines of therapy. Novel agents including selinexor- and venetoclax-based combinations offer new therapeutic choices for relapsed/refractory MM. Furthermore, the trispecific CC-93269 represents the new generation of highly active T-cell engagers. Chimeric antigen receptor T-cell constructs show significant efficacy among patients with heavily pretreated relapsed/refractory MM; however, the sustainability of responses remains a challenge.